推荐产品
化驗
≥98% (HPLC)
形狀
powder
顏色
white to tan
溶解度
DMSO: ≥40 mg/mL
相關疾病
Alzheimer′s disease; cardiovascular diseases
儲存溫度
room temp
SMILES 字串
CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C
InChI
1S/C29H43NO4S/c1-17(2)22-14-25(20(7)8)27(26(15-22)21(9)10)16-28(31)30-35(32,33)34-29-23(18(3)4)12-11-13-24(29)19(5)6/h11-15,17-21H,16H2,1-10H3,(H,30,31)
InChI 密鑰
PTQXTEKSNBVPQJ-UHFFFAOYSA-N
應用
阿伐麦布已被用作Huh7.5.1细胞中酰基辅酶A：胆固醇酰基转移酶（ACAT）的抑制剂，以测试其与直接作用抗病毒药物（DAA）的组合效果，以及其对适应酸中毒的癌细胞中脂质滴积累的影响。它可以用作ACAT的抑制剂来评估克氏锥虫中胆固醇的酯化。
生化／生理作用
阿伐麦布（CI-1011）是一种口服生物可利用的Acyl-CoA:胆固醇O-酰基转移酶（ACAT）抑制剂。它最初作为一种抗惊厥药物被开发，并且被证明能够显著降低血浆总甘油三酯和VLDL-胆固醇，但后来的临床试验令人失望。ACAT也被作为阿尔茨海默病的潜在治疗靶点进行了研究。最近已经研究了阿伐麦布通过限制可扩散淀粉样蛋白-β（Abeta）的产生和增加清除来削弱淀粉样蛋白病变的作用。
法律資訊
根据辉瑞公司的协议出售，用于研究目的。
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Jasminder Sahi et al.
The Journal of pharmacology and experimental therapeutics, 306(3), 1027-1034 (2003-05-27)
In vitro and clinical studies were conducted to characterize the potential of avasimibe, an acyl-CoA/cholesterol acyltransferase inhibitor to cause drug-drug interactions. Clinically, 3- and 6-fold increases in midazolam (CYP3A4 substrate) oral clearance were observed after 50 and 750 mg of
Akira Miyazaki et al.
Current drug targets. Cardiovascular & haematological disorders, 5(6), 463-469 (2006-03-01)
Acyl-coenzyme A: cholesterol acyltransferase (ACAT) is an intracellular enzyme that catalyzes the formation of cholesterol esters from cholesterol and fatty acyl-coenzyme A. Animal experiments showed that ACAT inhibitors reduce plasma cholesterol levels by suppressing absorption of dietary cholesterol and by
Colin Berry et al.
Circulation, 115(14), 1851-1857 (2007-03-29)
The relative merits of quantitative coronary analysis (QCA) and intravascular ultrasound (IVUS) for the assessment of progression/regression in coronary artery disease are uncertain. To explore this subject further, we analyzed the angiographic and IVUS data derived from a contemporary clinical
Marcelo F Di Carli et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 52(9), 1369-1377 (2011-08-19)
The metabolic syndrome affects 25% of the U.S. population and greatly increases the risk of diabetes and coronary artery disease (CAD). We tested the hypothesis that the metabolic syndrome is associated with impaired coronary vasodilator function, a marker of atherosclerotic
Stephen G Worthley et al.
Pathophysiology of haemostasis and thrombosis, 36(1), 9-17 (2008-03-12)
The ability to modify the enzymatic processes involved in promoting atherosclerotic plaque disruption and to serially monitor atherosclerotic evolution could provide novel information in the management of patients with atherosclerosis. We studied the effects of a statin (atorvastatin) and its
商品
Discover Bioactive Small Molecules for Lipid Signaling Research
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门